The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
March 12th 2025
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.
Walgreens, Greater Than AIDS Team Up With Health Organizations to Provide Free HIV Testing
June 13th 2018On National HIV Testing Day on June 27, Walgreens and Greater Than AIDS will partner with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.
Read More
NCI-Designated Cancer Centers Endorse Goal of Eliminating HPV-Related Cancers
June 13th 2018The 70 National Cancer Institute (NCI)-designated cancer centers underscored the importance of increased HPV vaccination and evidence-based screening, with the goal of eliminating cancers caused by the human papillomavirus (HPV).
Read More
This Week in Managed Care: May 25, 2018
May 25th 2018This week, the top managed care stories include the finding that new guidelines will mean the number of people with hypertension will soar; research finds that most diabetes apps don’t lower glycated hemoglobin; and a health plan announced its plan to fight housing instability.
Watch
Early Initiation of Antiretroviral Therapy Can Prevent HIV-Related Brain Damage
May 23rd 2018Neurological damage begins early in infection, particularly during untreated infection, and worsens with the continued absence of combination antiretroviral therapy (cART). However, initiating cART may halt further deterioration, emphasizing the importance of early cART.
Read More
FDA Expands Indication for PrEP to Reduce Risk of HIV in Adolescents
May 18th 2018The FDA has approved an expanded indication for Gilead Science’s emtricitabine/tenofovir disoproxil fumarate (Truvada) to reduce the risk of HIV in at-risk adolescents. Truvada for pre-exposure prophylaxis (PrEP) was first approved for the use in adults in 2012.
Read More
Team Identifies HIV Hotspots to Target Prevention, Treatment Efforts
May 12th 2018Through an HIV heatmap, as well as an extensive survey and customized web-based software to connect social determinants with viral suppression rates, an HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.
Read More
Prostate, Lung Cancers Projected to Be Most Common Cancers Among HIV Population by 2030
May 9th 2018The total cancer burden among people living with HIV will decrease from 8150 cases in 2010 to 6690 cases in 2030, and prostate and lung cancers will emerge as the most common types of cancer facing the patient population.
Read More
Dr Aimee Tharaldson on Recently Approved Specialty Drugs, Upcoming Approvals to Watch
May 5th 2018Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, discusses specialty drugs that have recently been approved, and which we will likely see approved in the remainder of the year.
Watch
Tahir Amin: Increasing Access to Affordable HIV Drugs Through Patent Opposition
May 4th 2018Tahir Amin, DipLP, co-founder and co-executive director of the Initiative for Medicines, Access, and Knowledge, discusses the organization’s focus on patent opposition for HIV drugs, the results of their work, and what efforts are still needed.
Read More
Gaps in Care up to Nine Months Do Not Worsen Viral Load in Patients With HIV
May 2nd 2018Patients with gaps between HIV primary care visits of 6 months up until 9 months did not have a significant difference in viral suppression loads. However, with gaps of 12 months or more, 23% of patients became unsuppressed.
Read More
Long-Term Analysis Highlights Half Trillion Dollars Spent on HIV/AIDS
April 25th 2018Between 2000 and 2015, $562.6 billion was spent on HIV/AIDS, with most spending occurring in high-income and upper-income countries and out-of-pocket spending accounting for less than 10%, according to the first long-term, comprehensive analysis of funding for the disease.
Read More
Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs
April 24th 2018At the Academy of Managed Care Pharmacy's Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26, in Boston, Massachusetts, an overflow capacity crowd gathered for one of the meeting’s yearly highlights­: Specialty Pharmaceuticals in Development. Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, talked about the key trends in the specialty drug market, including cancer drugs, new competition, and orphan drugs.
Read More
What's New in Adult and Adolescent, Perinatal HIV Guidelines
April 20th 2018AIDSinfo, a portal from the National Institutes of Health, has outlined recent changes that have been made to the adult, adolescent, and perinatal HIV guidelines, including the incorporation of people-first language.
Read More
Patients With HIV Face Increased Risk of Mortality From Lung Cancer
April 18th 2018The increased risk of cancer in patients with HIV has been well defined, and some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from their cancer than patients without HIV.
Read More
This Week in Managed Care: April 13, 2018
April 13th 2018This week, the top managed care stories included President Donald Trump signing an executive order requiring the poor to get jobs or lose food and healthcare benefits; a CMS report found ethnic, racial, and gender disparities in Medicare Advantage plans; CDC highlighted the impact of HIV on America's youth.
Watch